Educational Notice
This article is written for researchers, clinicians, and informed adults seeking to understand the scientific literature on sermorelin. It is not medical advice, a treatment recommendation, or an endorsement of any specific use. Sermorelin was previously FDA-approved as Geref but was withdrawn from the US market in 2008 for commercial reasons. Current sermorelin products are compounded or research-grade, not the original FDA-approved formulation. It is prohibited in competitive sport under WADA regulations. Consult a qualified healthcare professional before making any health or treatment decisions.
Sermorelin occupies an unusual position in the growth hormone secretagogue landscape: it is the only compound in the GH Secretagogues cluster with a genuine history of FDA approval. Serono Laboratories received FDA approval for sermorelin acetate (brand name Geref) for the treatment of growth hormone deficiency in children. The compound was used in clinical practice, studied in adult populations with age-related GH decline, and accumulated a clinical evidence base that no other research peptide in this cluster approaches.
Geref was withdrawn from the US market in 2008—not because of safety concerns, not because of efficacy failures, but for commercial reasons. The GH replacement market had shifted toward long-acting GH formulations with more convenient dosing schedules; a twice-daily subcutaneous injection that required precise timing was commercially uncompetitive. The compound’s regulatory history and clinical data remained intact. Sermorelin then entered the compounding pharmacy market and, eventually, the research chemical market.
Understanding sermorelin requires holding two things simultaneously: this compound has a stronger clinical evidence base and a cleaner regulatory history than almost any research peptide in common use, and the sermorelin products available today are not the FDA-approved Geref. They are compounded or research-grade products without the manufacturing standards, purity guarantees, or post-market surveillance of a regulated pharmaceutical. The compound’s evidence history is real. The products currently sold under that name are not subject to the oversight that generated that history.
Table of Contents
- What Is Sermorelin?
- Origins and Regulatory History
- Mechanism of Action
- Key Research Areas and Studies
- Common Claims versus Current Evidence
- The Human Evidence Landscape
- Safety, Risks, and Limitations
- Legal and Regulatory Status
- Research Protocols and Laboratory Practices
- Dosing in Published Research
- Dosing in Independent Self-Experimentation Communities
- Frequently Asked Questions
- Related Peptides: How Sermorelin Compares
- Summary and Key Takeaways
- Selected References and Key Studies
- Further Reading and References
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Quick Facts
| Type | Synthetic 29-amino acid GHRH analog (GHRH(1-29)NH₂) |
| Also known as | GHRH(1-29); Geref (brand name, withdrawn); sermorelin acetate |
| Molecular weight | ~3358 Da |
| Target receptor | GHRHR (growth hormone-releasing hormone receptor) |
| Mechanism | GHRHR agonist → pulsatile pituitary GH release |
| Plasma half-life | ~10–20 minutes (subcutaneous administration) |
| GH profile | Pulsatile—produces discrete GH pulses matching physiological pattern |
| Route of administration | Subcutaneous injection (research and clinical use) |
| Developer | Serono Laboratories; later FDA-approved as Geref (Serono/EMD Serono) |
| FDA status | Category 3—was FDA-approved as Geref; withdrawn from US market 2008 for commercial reasons, not safety |
| WADA status | Prohibited—S2 (Peptide Hormones, Growth Factors, and Related Substances) |
| Evidence tier | Clinical Trials / Prior FDA Approval — strongest regulatory history in the cluster |
| Key distinction | Only compound in this cluster with a history of FDA approval; pulsatile GH profile; physiologically closest to natural GHRH |
What Is Sermorelin?
Sermorelin is a synthetic analog of the first 29 amino acids of human growth hormone-releasing hormone (GHRH). GHRH is a 44-amino acid hypothalamic peptide; sermorelin represents the biologically active N-terminal fragment sufficient for full GHRHR binding and activation. The full 44-amino acid sequence is not required—the first 29 residues carry all the receptor-binding and signaling information necessary to stimulate pituitary GH secretion.
Sermorelin acts at the GHRHR expressed on pituitary somatotroph cells. Binding activates Gs-coupled adenylyl cyclase, increasing intracellular cAMP and activating PKA, which drives exocytosis of stored GH granules. The result is a discrete, physiological GH pulse that follows the same signaling pathway as the natural hypothalamic GHRH pulse. Critically, somatostatin and IGF-1 negative feedback mechanisms remain fully functional during sermorelin administration—the pituitary is stimulated, but the brakes remain engaged. This is the pharmacological basis for the clinical argument that sermorelin is safer than direct GH injection.
Plain English
Sermorelin tells your pituitary to release GH, but your brain’s safety brake (somatostatin) still works normally. If GH gets too high, the brake kicks in automatically. This is why sermorelin can’t push GH to dangerous levels the way direct GH injections can—the system regulates itself.
With a plasma half-life of approximately 10–20 minutes following subcutaneous injection, sermorelin is among the shorter-acting compounds in the cluster. The GH pulse it produces peaks within 30–60 minutes and returns to baseline relatively quickly, mimicking the natural pulsatile pattern of GH secretion more closely than any other compound in the cluster except CJC-1295 without DAC.
Origins and Regulatory History
GHRH was identified and characterized in 1982 by two groups simultaneously—Guillemin and colleagues at the Salk Institute and Vale and colleagues at the Salk as well—identifying it in tumor tissue from patients with acromegaly (excess GH). This discovery opened the door to synthetic GHRH analogs as therapeutic compounds for GH deficiency.
Serono Laboratories developed sermorelin acetate and obtained FDA approval for the treatment of idiopathic growth hormone deficiency in children under the brand name Geref. The approval was based on clinical trial data demonstrating GH stimulation and growth promotion in GH-deficient pediatric patients. Geref was used in clinical practice and accumulated post-market safety data.
In the mid-1990s through early 2000s, several research groups studied sermorelin in adult populations—particularly in older adults experiencing the age-related decline in GH secretion known as somatopause. These studies demonstrated IGF-1 normalization, body composition improvements, and sleep quality enhancement in older adults with low GH, generating interest in sermorelin as an anti-aging therapeutic.
EMD Serono withdrew Geref from the US market in 2008, citing commercial rather than safety reasons. The shift toward long-acting somatropin formulations and changing market dynamics made the twice-daily sermorelin protocol uncompetitive commercially. Sermorelin subsequently became available through compounding pharmacies and, increasingly, through research chemical suppliers.
The Regulatory Context
Sermorelin’s FDA approval history means it has been through the regulatory process, its manufacturing specifications and pharmacology have been reviewed, and it has post-market safety monitoring data from clinical use. None of this applies to compounded or research-grade sermorelin sold today. The compound’s evidence history was generated under pharmaceutical-grade manufacturing standards.
Mechanism of Action
Sermorelin binds the GHRHR on pituitary somatotroph cells through its N-terminal sequence (the first 29 amino acids are sufficient for full agonist activity at the receptor). Receptor binding activates Gs protein coupling, stimulating adenylyl cyclase and raising intracellular cAMP. PKA activation follows, triggering calcium influx and exocytosis of GH-containing secretory granules. The GH pulse enters circulation within minutes and peaks at 15–45 minutes post-injection.
The hypothalamic–pituitary feedback architecture remains intact during sermorelin administration. Rising GH and IGF-1 stimulate hypothalamic somatostatin release, which suppresses further GH secretion. This means sermorelin cannot produce the pathologically high GH levels achievable with exogenous GH injection—the pituitary’s own regulatory mechanisms impose a ceiling. This regulatory preservation is the mechanistic basis for the clinical preference for secretagogues over direct GH replacement among some endocrinologists.
Because sermorelin acts specifically at the pituitary GHRHR, it does not carry the cortisol-stimulating or appetite-stimulating effects associated with GHS-R1a agonists like GHRP-2 or GHRP-6. The endocrine profile of GHRHR agonists is generally cleaner than GHS-R1a agonists in this respect.
Plain English
Because sermorelin works through the GHRH receptor—not the ghrelin receptor—it triggers GH release without the cortisol spikes, hunger surges, or prolactin bumps that plague GHS-R1a agonists like GHRP-2 and GHRP-6. Cleaner signal, fewer side effects.
Key Research Areas and Studies
Sermorelin’s evidence base is the most clinically substantial of any compound in this cluster. Key areas include GH deficiency treatment in children (the basis for FDA approval), body composition and GH restoration in older adults, sleep quality, and adult GH deficiency.
GH Deficiency in Children
The FDA-approved indication for Geref was idiopathic GH deficiency in children. Multiple studies demonstrated that sermorelin administered at bedtime (0.03 mg/kg SC) produced adequate GH stimulation for growth in GH-deficient pediatric patients. This is the highest level of clinical evidence for any application of sermorelin.
Adult Somatopause
Walker et al. (1994), Corpas et al. (1992), and related studies in healthy older men demonstrated that daily sermorelin administration increased IGF-1 levels, improved body composition (reduced fat mass, preserved or increased lean mass), enhanced slow-wave sleep, and improved quality of life measures. These studies form the basis for much of the anti-aging interest in sermorelin.
Sleep
GHRH and slow-wave sleep are bidirectionally linked. Exogenous GHRH promotes slow-wave sleep in humans, and slow-wave sleep is the period of maximal GH pulse magnitude. Sermorelin studies confirm improved sleep EEG parameters (increased slow-wave sleep) with pre-bedtime administration—one of the more mechanistically coherent and better-documented secondary effects for any compound in this cluster.
Plain English
GHRH and deep sleep are wired together: your biggest natural GH pulse happens during slow-wave sleep. Injecting sermorelin before bed amplifies that pulse—and studies show it actually increases the amount of deep sleep you get. This is one of the better-supported secondary effects in the entire cluster.
Common Claims versus Current Evidence
| Claim | Evidence | Verdict |
|---|---|---|
| Sermorelin stimulates GH release | Established in multiple clinical trials and clinical practice over decades of use. Pulsatile GH stimulation via GHRHR is sermorelin’s confirmed primary effect. | Supported |
| Sermorelin is safer than GH replacement | Sermorelin works through the body’s own regulatory mechanisms—pituitary feedback and somatostatin still operate, limiting GH excess. Direct GH injection bypasses these limits entirely. The relative safety profile versus GH replacement is clinically plausible and broadly accepted in endocrinology; no direct head-to-head RCT quantifies the difference. | Clinically Plausible |
| Sermorelin improves body composition in GH-deficient adults | Multiple trials in GH-deficient and GH-declining populations show improvements in lean mass, fat mass, and bone mineral density with sermorelin treatment. The evidence here is stronger than for most research peptides in this cluster. | Supported in GH-Deficient Populations |
| Sermorelin improves body composition in healthy adults without GH deficiency | Less clearly established. Healthy adults with normal GH axes respond to sermorelin with measurable GH elevation, but the clinical impact on body composition in the absence of GH deficiency is more modest than in GH-deficient populations and less consistently documented. | Partially Supported |
| Sermorelin improves sleep quality | GHRH and GH release are intimately linked with slow-wave sleep. GHRH administration increases slow-wave sleep in human studies. Whether sermorelin specifically improves subjective or objective sleep quality in non-deficient adults is less well-documented than the mechanistic relationship suggests. | Mechanistically Supported—Clinical Evidence Limited |
| Sermorelin reverses aging (anti-aging effect) | Sermorelin addresses GH decline associated with aging (somatopause). Whether correcting somatopause with a GH secretagogue produces anti-aging effects in humans is conceptually appealing but not established in controlled trials. Benefits for specific parameters (body composition, bone density) in older adults with low GH are better supported than general anti-aging claims. | Partially Supported—Specific Parameters Only |
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
The Human Evidence Landscape
Sermorelin stands apart from the other compounds in this cluster in terms of human evidence quality. It has FDA-approved status history, post-market clinical use data, and multiple published clinical trials in both pediatric and adult populations. For adult somatopause applications, the evidence base—while not consisting of large Phase III trials—is substantially stronger than preclinical-only or Phase I-only data.
The limitations are real. The adult studies are generally small and of short duration. The most directly relevant population for current community use—healthy adults with normal GH axes seeking body composition or performance enhancement—is not the population studied in the clinical trials, which focused on GH-deficient or GH-declining older adults. The evidence that sermorelin produces body composition changes in healthy young adults with normal GH is less robust than the evidence for GH-deficient populations.
Additionally, the commercial withdrawal from the market means there is no ongoing pharmaceutical-grade sermorelin production with regulatory oversight. Products sold as sermorelin today are compounded or research-grade. The clinical evidence history was generated with pharmaceutical-grade product. Whether compounded sermorelin preparations reliably match the pharmacological profile of Geref depends on manufacturing quality that varies by supplier.
Safety, Risks, and Limitations
Established Clinical Safety Profile
Sermorelin’s clinical use history provides more safety data than any other compound in this cluster. Common adverse effects in clinical trials: injection site reactions (mild, transient), flushing, and headache. In pediatric GH deficiency studies, no serious adverse effects attributable to sermorelin were identified. The compound’s mechanism of action—stimulating pituitary GH release through normal feedback-regulated pathways—limits the risk of GH excess.
Physiological Safety Mechanism
Unlike direct GH injection or very long-acting GH secretagogues, sermorelin’s effects are constrained by the body’s own somatostatin feedback. Excessive GH elevation triggers somatostatin release, which reduces the response to subsequent sermorelin doses. This self-limiting mechanism provides a pharmacological safety margin that is not present with exogenous GH or with continuous GH secretagogues like CJC-1295 with DAC.
Compounding Quality Concerns
Post-market compounded sermorelin is not subject to the manufacturing standards that governed Geref. Purity, potency, and sterility of compounded products vary by compounding pharmacy. Research-grade sermorelin from non-pharmaceutical suppliers carries even less quality assurance. The compound’s excellent clinical safety profile was established with pharmaceutical-grade product—that safety data does not automatically transfer to products of unknown quality.
Antibody Formation
Some patients in clinical trials developed anti-sermorelin antibodies over time. In most cases these antibodies were non-neutralizing and did not attenuate clinical response. Persistent antibodies with loss of GH stimulation response were rarely observed. Periodic monitoring of IGF-1 levels in clinical protocols was recommended to detect attenuated response.
Legal and Regulatory Status
FDA Status
Sermorelin is currently FDA Category 3—not approved for any indication—because Geref was withdrawn from the market. The withdrawal was commercial, not regulatory; the FDA did not revoke approval for safety reasons. Compounding pharmacies may produce sermorelin under FDA compounding regulations; the regulatory status of compounded sermorelin has been subject to changing FDA guidance. Verify current compounding policy rather than relying on any fixed statement here.
WADA Status
WADA Prohibition
Sermorelin is prohibited under WADA S2 both in-competition and out-of-competition, as a GHRH analog. Athletes subject to anti-doping testing must treat this as a hard prohibition.
Research Protocols and Laboratory Practices
Sermorelin is supplied as lyophilized powder reconstituted with bacteriostatic water. Storage: lyophilized at 2–8°C (35–46°F), protected from light; reconstituted solution refrigerate and use within 28 days. Pre-sleep timing is the most studied and mechanistically supported administration timing. Standard subcutaneous injection technique applies.
Reconstitution vs. Dosing Syringes
Use one syringe for reconstitution, a separate syringe for each dose. Rotate injection sites. The short half-life means pre-sleep timing has direct physiological relevance—sermorelin administered 30–60 minutes before sleep onset should coincide with the early slow-wave sleep period when endogenous GH pulse magnitude is greatest.
Dosing in Published Research
| Study / Source | Population | Dose | Route | Frequency | Duration | Key Findings |
|---|---|---|---|---|---|---|
| Walker RF, et al. J Gerontol 1994 | Healthy older men (mean age 69) | 0.5–2 mg/day | SC | Once daily (before sleep) | 3 months | Significant GH and IGF-1 increases; improved sleep quality; favorable body composition trends |
| Vittone J, et al. J Clin Endocrinol Metab 1997 | GH-deficient and age-related GH decline | 2 mcg/kg SC or 15 mcg/kg intranasal | SC or intranasal | Twice daily | 6 months | SC route superior to intranasal; IGF-1 normalization in GH-deficient patients; lean mass improvement |
| Geref prescribing history (FDA-approved use) | Children with GH deficiency | 0.03 mg/kg/day | SC | Once daily at bedtime | Until epiphyseal closure | Established GH stimulation and growth promotion in GH-deficient children; basis for FDA approval |
| Corpas E, et al. J Clin Endocrinol Metab 1992 | Healthy older men | 0.5 mg/day increasing to 2 mg/day | SC | Daily | 3 months | Dose-dependent IGF-1 increase; favorable body composition changes; sleep EEG improvement |
Dosing in Independent Self-Experimentation Communities
| Protocol Parameter | Typical Community Range | Notes |
|---|---|---|
| Dose per injection | 100–500 mcg; 200 mcg most common | FDA-approved pediatric dose was 0.03 mg/kg; adult community protocols use a flat 200–500 mcg dose. No Phase III dose-optimization in adults established the optimal dose. |
| Frequency | 1–2× daily; most common: single injection before sleep | Pre-sleep dosing reflects the GHRH–slow-wave sleep relationship. Some protocols use morning and bedtime dosing. |
| Combination partner | Sometimes combined with ipamorelin or GHRP-2 (GHS-R1a agonist) | Pharmacological rationale same as CJC-1295 (no DAC) + ipamorelin: GHRHR + GHS-R1a dual-pathway synergy. Sermorelin is a shorter-acting GHRHR agonist than CJC-1295 (no DAC) but the combination logic is sound. |
| Cycle length | 12–24 weeks; longer cycles used more often than with synthetic peptides | Sermorelin’s prior clinical use and perceived lower risk profile supports longer protocols in community use. Not evidence-based. |
| Distinct from GH replacement | Sermorelin preserves pituitary feedback mechanisms—GH excess is self-limiting via somatostatin | This is the key practical difference cited by clinicians who prefer secretagogues over direct GH injection. |
Frequently Asked Questions
Was sermorelin really FDA-approved?
Yes. Sermorelin acetate (Geref) was FDA-approved for the treatment of idiopathic GH deficiency in children. It was withdrawn from the US market in 2008 for commercial reasons—not for safety or efficacy concerns. The FDA did not revoke approval; the manufacturer discontinued the product.
Is sermorelin safer than GH injections?
The theoretical case is strong: sermorelin works through pituitary feedback mechanisms that limit GH excess, while direct GH injection bypasses these limits. In clinical practice, sermorelin has not produced the adverse effects (acromegaly risk, edema, carpal tunnel syndrome, insulin resistance) associated with supraphysiological GH use. No large head-to-head comparative safety trial has quantified the difference. The practical conclusion—that secretagogue-based GH stimulation has a more constrained risk profile than exogenous GH—is accepted in endocrinology but has not been formally proven.
How does sermorelin compare to CJC-1295 without DAC?
Both are GHRHR agonists producing pulsatile GH stimulation. The key difference is half-life: sermorelin ~10–20 minutes versus CJC-1295 without DAC ~30 minutes. Both produce physiologically appropriate GH pulses; CJC-1295 without DAC’s longer half-life produces a somewhat more sustained pulse. Sermorelin has substantially more clinical data and a prior FDA approval history. CJC-1295 without DAC is more commonly used in current community protocols, possibly because it requires less frequent dosing for equivalent GH stimulation. Both can be combined with GHS-R1a agonists (ipamorelin, GHRP-2) on the same dual-pathway rationale.
Does sermorelin require cycling?
The anti-antibody concern and axis preservation rationale support periodic breaks in long protocols. Clinical studies used durations of 3–6 months. Community protocols vary. The physiological self-limiting mechanism (somatostatin feedback) provides some protection against GH excess, but this does not mean indefinite continuous use is without risk. Periodic breaks and IGF-1 monitoring are prudent.
Related Peptides: How Sermorelin Compares
| Compound | Receptor | Route | GH Profile | Appetite | Half-life | Evidence Tier | FDA Status |
|---|---|---|---|---|---|---|---|
| Ipamorelin | GHS-R1a | Peptide SC | Moderate pulse | Minimal | ~2 hr | Preclinical / Phase I | Cat. 3 |
| CJC-1295 no DAC | GHRHR | Peptide SC | Moderate pulse | None | ~30 min | Preclinical / Phase I | Cat. 3 |
| CJC-1295 with DAC | GHRHR (albumin-bound) | Peptide SC | Strong, sustained ~14 days | None | ~14 days | Phase I/II | Cat. 3 |
| Sermorelin | GHRHR | Peptide SC | Moderate pulse | None | ~10–20 min | Clinical / Prior FDA approval | Cat. 3 |
| MK-677 | GHS-R1a | Non-peptide oral | Strong, sustained ~24 hr | Moderate | ~24 hr | Phase II/III | Cat. 3 |
| Tesamorelin | GHRHR | Peptide SC | Moderate pulse | None | ~26–38 min | Approved Drug (HIV lipodystrophy) | FDA approved — Egrifta |
| Compound | Type | Receptor | GH Potency | Cortisol / ACTH | Appetite Effect | Half-Life | Route | FDA Status | WADA Status | Evidence Tier | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipamorelin | Synthetic pentapeptide GHS | GHS-R1a | Moderate | Minimal at research doses | Minimal | ~2 hr (subcutaneous) | Subcutaneous injection | Category 3 — not available via US compounding | Prohibited — S2 | Tier 2 — Clinical Trials (Phase I) | Most selective GHRP: GH release without cortisol, ACTH, or prolactin elevation at research doses |
| CJC-1295 (no DAC) | Synthetic GHRH analog (modified GRF 1-29) | GHRH-R | Moderate (amplifies when paired with GHS-R1a agonist) | None | None | ~30 min | Subcutaneous injection | Category 3 — not available via US compounding | Prohibited — S2 | Tier 3 — Preclinical / Mechanistic | Short-acting GHRH analog; preserves pulsatile GH physiology. Pharmacologically paired with ipamorelin via complementary receptor pathway |
| CJC-1295 (with DAC) | Synthetic GHRH analog with Drug Affinity Complex | GHRH-R | Strong (sustained) | None | None | ~6–8 days | Subcutaneous injection | Category 3 — not available via US compounding | Prohibited — S2 | Tier 2 — Clinical Trials (Phase I/II) | DAC extends half-life to ~1 week; produces sustained (non-pulsatile) GH elevation. NOT interchangeable with no-DAC version |
| Sermorelin | Synthetic GHRH analog (GRF 1-29) | GHRH-R | Moderate | None | None | ~10–20 min | Subcutaneous injection | Previously FDA-approved (Geref); discontinued commercially | Prohibited — S2 | Tier 1 — Approved (historically) | Only GH secretagogue with prior FDA approval history. Very short half-life limits practical utility |
| MK-677 (Ibutamoren) | Non-peptide GHS (spiroindoline) | GHS-R1a | Strong (sustained over 24 hr) | Transient mild elevation | Significant (hunger, weight gain) | ~4–6 hr (oral bioavailability) | Oral | Category 3 — not FDA-approved | Prohibited — S2 | Tier 2 — Clinical Trials (Phase II) | Only orally bioavailable GHS-R1a agonist. Most extensive human clinical dataset in the class. Appetite and insulin resistance are dose-limiting |
| GHRP-2 | Synthetic hexapeptide GHS | GHS-R1a | Strong (most potent classic GHRP) | Significant — cortisol and ACTH stimulation | Moderate | ~25–30 min | Subcutaneous injection | Category 3 — not available via US compounding | Prohibited — S2 | Tier 3 — Preclinical / Mechanistic | Most potent GH release of classic GHRPs, but cortisol/ACTH co-stimulation works against anabolic intent |
| GHRP-6 | Synthetic hexapeptide GHS | GHS-R1a | Strong | Significant — cortisol and ACTH stimulation | Strong (intense hunger) | ~15–20 min | Subcutaneous injection | Category 3 — not available via US compounding | Prohibited — S2 | Tier 3 — Preclinical / Mechanistic | First widely used GHRP. Intense appetite stimulation mirrors ghrelin signaling. Least selective of the class |
| Hexarelin | Synthetic hexapeptide GHS | GHS-R1a | Strong | Significant — cortisol and ACTH stimulation | Moderate | ~70 min | Subcutaneous injection | Category 3 — not available via US compounding | Prohibited — S2 | Tier 3 — Preclinical / Mechanistic | Rapid receptor desensitization limits sustained use. GH response attenuates more steeply over repeated dosing than other GHRPs |
Summary and Key Takeaways
Sermorelin has the strongest regulatory pedigree and the most substantial human evidence base of any compound in the Growth Hormone Secretagogues cluster. Its mechanism—pulsatile GH stimulation through intact feedback-regulated pathways—is the most physiologically conservative approach to GH secretagogue use. Its evidence for body composition and sleep benefits in GH-declining older adults is genuinely solid by research peptide standards.
- Sermorelin is a 29-amino acid GHRH analog that produces pulsatile GH stimulation via GHRHR activation, closely mimicking natural GHRH physiology.
- The only compound in this cluster with a history of FDA approval (Geref, withdrawn 2008 for commercial reasons, not safety).
- Body composition and sleep evidence in GH-deficient and older adult populations is stronger than for most research peptides. Evidence in healthy young adults with normal GH is more limited.
- Pituitary feedback mechanisms remain intact—GH excess is physiologically self-limiting in a way that direct GH injection is not.
- Products available today are compounded or research-grade; the clinical evidence was generated with pharmaceutical-grade Geref.
- WADA-prohibited under S2 both in- and out-of-competition.
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Selected References and Key Studies
- Corpas E, et al. Human growth hormone and human aging. Endocr Rev. 1993;14(1):20–39. — Comprehensive review of somatopause and GH secretagogue rationale.
- Walker RF, et al. Effects of growth hormone-releasing hormone on sleep and growth hormone secretion in healthy elderly men. J Gerontol. 1994;49(1):B9–16.
- Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89–96.
- Thorner MO, et al. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Endocrinol (Oxf). 1997;46(1):121–8.
- Geref (sermorelin acetate) prescribing information. Serono Laboratories, 1997. FDA NDA 019888.
Further Reading and References
- CJC-1295 (no DAC) article at peptidings.com/peptides/cjc-1295/ — most common sermorelin analog comparison
- Ipamorelin article at peptidings.com/peptides/ipamorelin/ — GHS-R1a combination partner
- Tesamorelin article at peptidings.com/peptides/tesamorelin/ — the currently FDA-approved GHRH analog
- Growth Hormone Secretagogues Cluster Hub at peptidings.com/peptides/growth-hormone-secretagogues/
Disclaimer
This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Nothing in this article should be interpreted as an endorsement of any compound for human use outside of properly conducted clinical trials.
Sermorelin information is provided for research and educational purposes only. Readers are responsible for understanding and complying with all applicable laws in their jurisdiction.
All citations link to primary sources where available. Where cited studies are limited to animal models or early-phase trials, that limitation is stated explicitly in the text and is not minimized.
← Previous
Next →